Home

Biotech

Broadband

B2B Internet

Europe 2001

Internet

Internet 
Architecture

Internet 
Infrastructure

Market 2000+

Oil Services

Pharmaceutical

Regional Bank

Retail

Semiconductor

Software

Telecom

Utilities

Wireless
AstraZeneca PLC (NYSE:AZN)9/3/2010
most recent headlinesmore headlines:       
TUESDAY, JUNE 29, 2010
7:06 PMCRESTOR(R) Patent Upheld By US Court - PR Newswire
SATURDAY, JUNE 26, 2010
2:45 PMDapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control in Patients With Type 2 Diabetes Inadequately Controlled With Insulin - BusinessWire
10:00 AM52-Week Study Finds ONGLYZA(TM) (saxagliptin) When Added to Metformin Was Non-Inferior to Titrated Glipizide When Added to Metformin in Reducing Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus - BusinessWire
9:30 AMONGLYZA(TM) (saxagliptin) With Metformin as Initial Combination Therapy Provided 76-Week Long-Term Glycemic Control in Treatment-Naive Adults With Type 2 Diabetes - BusinessWire
TUESDAY, JUNE 22, 2010
10:00 AMDapagliflozin as Monotherapy Demonstrated Improved Glycemic Control in Treatment-Naive Adults with Type 2 Diabetes - BusinessWire
FRIDAY, JUNE 18, 2010
4:09 PM$103 Million Settlement Reached in Astra Zeneca Case, Announced Hagens Berman - BusinessWire
THURSDAY, JUNE 10, 2010
8:00 AMRon Laufer named Senior Managing Director of MedImmune Ventures - PR Newswire
WEDNESDAY, JUNE 09, 2010
9:14 AMDIA Annual Meeting Highlights End of Paper-Based Systems via SAFE-BioPharma Industry Standard - BusinessWire
MONDAY, JUNE 07, 2010
9:18 AMFirst Phase III Trial With Definitive Results In Advanced Medullary Thyroid Cancer Shows Statistically Significant Extension of Progression Free Survival For Patients - PR Newswire
9:14 AMFirst Phase III Trial With Definitive Results in Advanced Medullary Thyroid Cancer Shows Statistically Significant Extension of Progression Free Survival for Patients - PR Newswire


Quotes delayed at least 15 minutes. Market data provided by Interactive Data.
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

HOLDRS Defined |  HOLDRS Outstanding  |  FAQ  |  Proxies by email  |  Investment Strategies
Spin-Offs & Changes  |  Current Trading  |  Download a Prospectus  |  Site Map

Merrill Lynch, Pierce, Fenner & Smith Incorporated is a registered broker-dealer and a wholly-owned subsidiary of Bank of America Corporation.
Securities Products: Are Not FDIC Insured • Are Not Bank Guaranteed • May Lose Value.

The information in this Internet site is directed at, and is intended for distribution to, and for use by, persons in the U.S. only, and is not intended for distribution to or use by any person in any other jurisdiction. Merrill Lynch does not warrant the accuracy or completeness of any price, tax, cost basis, or other information on this site, or any investment, tax or other benefits associated with HOLDRS.

The information on HOLDRSSM contained in this Internet site is solely for informational purposes and does not constitute either an offer to sell or the solicitation of an offer to buy HOLDRS. This information on HOLDRS is not, and is not intended to be, a complete discussion of all material information you should know about HOLDRS. If you are considering whether to purchase a HOLDRS security, you should carefully read the relevant prospectus prior to making a purchase. You should not rely on the information contained in this Internet site. Please view Terms of Use and Legal Notices for additional important legal information and the terms and conditions governing your use of this site.

U.S. Patent Pending.
HOLDRS and HOLding Company Depositary ReceiptS are service marks of Merrill Lynch & Co., Inc.

© Copyright 2000, Merrill Lynch, Pierce, Fenner & Smith Incorporated. Member, Securities Investor Protection Corporation (SIPC). All rights reserved.